Performance of the Italian version of the Subjective Well-Being Under Neuroleptic (SWN) scale in schizophrenic outpatients

Pharmacopsychiatry

Volumn 39, Issue 3, 2006, Pages 81-84

  Balestrieri, M ^a   Giaroli, G ^b   Mazzi, M ^b   Bellantuono, Cesario ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTEGRATION; ITALY; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; OUTPATIENT; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; CROSS-CULTURAL COMPARISON; DELUSIONS; DRUG THERAPY, COMBINATION; FEMALE; FOCUS GROUPS; HUMANS; ITALY; LANGUAGE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PATIENT SATISFACTION; PERSONALITY INVENTORY; PSYCHOMETRICS; PSYCHOTIC DISORDERS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33745130041     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-941480     Document Type: Article

References (27)

1. Jo B. American Psychiatric Association. DSM IV TR, 2000
2. Arnt J. Pharmacological differences of classical and novel antipsychotics. Int Clin Psychopharmacol 1998; 13: 7-14
3. Awad A-G. Quality of life issues on medicated schizophrenic patients. In: Nasrhallah H, Shirqui C, Editors. Contemporary Issues in Treatment of Schizophrenia APA Press, Washington DC: USA: 1995: p. 833-846
4. Carrick R, Mitchell A, Powell R, Lloyd K. The quest for well-being: a qualitative study of the experience of taking antipsychotic medication. Psychol Psychother 2004; 77: 19-33
5. De Haan L, Lavalaye J, Linszen D, Dingemans P-M, Booje J. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000; 157: 1019-1020
6. De Haan L, Van Bruggen M, Lavelaye J, Booij J, Dingemans P-M, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent onset schizophrenia treated with low dose olanzapine or haloperidol: a randomized, double bind study. Am J Psychiatry 2003; 160: 303-309
7. De Haan L, Lavalaye J, Van Bruggen M, Van Nimwegen L, Booij J, Van Amesloort T et al. Subjective experience and dopamine D2 receptors occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry 2004; 49: 290-296
8. Gerlach J, Larsen EB. Subjective experience and mental side effects of antipsychotic treatment. Acta Psychiatr Scand 1999; 99: 113-117
9. Hogan TP, Awad AG, Eastwood R. A self report scale predicting of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177-183
10. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347-352
11. Kampman O, Lehtien K, Lassila V, Poutanen O, Koivisto AM. Attitudes towards neuroleptic treatment: reliability and validity of Attitude towards Neuroleptic Treatment (ANT) questionnaire. Schizophr Res 2000; 45: 223-234
12. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002; 162: 3-10
13. Kluge M, Wehmeier PM, Dittman RW, Lenger F, Czekalla L, Lehemann M et al. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapina; changes in psychopathology and subjective well-being. Pharmachopsych 2005; 38: 6-12
14. Knudsen HC, Vazquez-Barquero JL, Welcher B, Gaite L, Becker T, Chisholm D et al. Translation and cross cultural adaptation of outcome measurement for schizophrenia. Br J Psychiatry 2000; 177: 8-14
15. Lambert M, Graf Shimmelmann B, Karow D, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs-concepts. Measurement and Clinical relevance. Pharmachopsychiatry; 36 Suppl 3: S181-190
16. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Pscychopharmacol 1995; 10: 133-138
17. Naber D, Karow A. Good tolerability equals good results: the patient's prospective. Eur Neuropsychopharmacol 2001; 11: 391-396
18. Naber D, Moriz S, Lambert M, Pajonk R, Holzbach R, Mass R, Andersen B. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50: 79-88
19. Naber D, Karow A, Lambert M. Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration. Curr Opin Psychiatry 2002; 15: 31-36
20. Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, Bender S et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005; 111: 106-115
21. Ramaekers JC, Louwerens JW, MuntJewerff ND, Milius H, de Bie A, Rosenzweig P, Patat A et al. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol 1999; 19: 209-221
22. Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia. Compr Psychiatry 2000; 41: 446-449
23. Rossi A, Arduini L, De Cataldo S, Stratta P. Gli aspetti soggettivi del trattamento con farmaci antipsicotici: studio di validazione della versione italiana della Drug Attitude Inventory (DAI). Epidemiol Psichiatr Soc 2001; 10: 107-114
24. Simonsen E, Mortensen EL. Difficulties in translation of personality scales. J Personal Disord 1990; 4: 290-306
25. Van Putten T. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477-480
26. Voruganti L, Awad G. Personal evaluation of transitions in treatment (PETiT) a scale to measure subjective aspects of antipsichotic drug therapy in schizophrenia. Schizophr Res 2002; 56: 37-46
27. Weiden PJ, Rapkin B, Mott T. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull 1994; 29: 269-275